Cargando…

Diacylglycerol Enhances the Effects of Alpha‐Linolenic Acid Against Visceral Fat: A Double‐Blind Randomized Controlled Trial

OBJECTIVE: To investigate the effect of alpha‐linolenic acid‐rich diacylglycerol (ALA‐DAG) compared with alpha‐linolenic acid‐rich triacylglycerol (ALA‐TAG) on visceral fat area (VFA) in people with overweight. METHODS: Subjects with overweight were recruited to a randomized, double‐blind, controlle...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Shinichiro, Mori, Atsuko, Osaki, Noriko, Katsuragi, Yoshihisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638073/
https://www.ncbi.nlm.nih.gov/pubmed/28851088
http://dx.doi.org/10.1002/oby.21938
_version_ 1783270691202662400
author Saito, Shinichiro
Mori, Atsuko
Osaki, Noriko
Katsuragi, Yoshihisa
author_facet Saito, Shinichiro
Mori, Atsuko
Osaki, Noriko
Katsuragi, Yoshihisa
author_sort Saito, Shinichiro
collection PubMed
description OBJECTIVE: To investigate the effect of alpha‐linolenic acid‐rich diacylglycerol (ALA‐DAG) compared with alpha‐linolenic acid‐rich triacylglycerol (ALA‐TAG) on visceral fat area (VFA) in people with overweight. METHODS: Subjects with overweight were recruited to a randomized, double‐blind, controlled, parallel‐group designed trial and randomly allocated to two groups that consumed either 2.5 g/d ALA‐TAG or ALA‐DAG for 12 weeks. Two 4‐week nontreatment periods were placed before and after the treatment period. One hundred fourteen subjects (n = 57 in the ALA‐TAG group, n = 57 in the ALA‐DAG group) were enrolled into the analysis set for efficacy evaluation. RESULTS: The VFA and BMI were significantly decreased by the ALA‐DAG treatment with a treatment‐by‐time interaction compared with the ALA‐TAG treatment (P < 0.05). Additionally, the change from baseline of the fasting serum TAG concentration at week 12 was significantly decreased by ALA‐DAG treatment compared with ALA‐TAG treatment (P < 0.05). Safety parameters such as urinary measurements, hematologic parameters and blood biochemistry, and the incidence of adverse events did not differ significantly between groups, and no ALA‐DAG–associated adverse effects were detected. CONCLUSIONS: Incorporation of ALA‐DAG in a regular diet for 12 weeks may lead to a reduction in VFA, BMI, and serum TAG in men and women with overweight.
format Online
Article
Text
id pubmed-5638073
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-56380732017-10-25 Diacylglycerol Enhances the Effects of Alpha‐Linolenic Acid Against Visceral Fat: A Double‐Blind Randomized Controlled Trial Saito, Shinichiro Mori, Atsuko Osaki, Noriko Katsuragi, Yoshihisa Obesity (Silver Spring) Original Articles OBJECTIVE: To investigate the effect of alpha‐linolenic acid‐rich diacylglycerol (ALA‐DAG) compared with alpha‐linolenic acid‐rich triacylglycerol (ALA‐TAG) on visceral fat area (VFA) in people with overweight. METHODS: Subjects with overweight were recruited to a randomized, double‐blind, controlled, parallel‐group designed trial and randomly allocated to two groups that consumed either 2.5 g/d ALA‐TAG or ALA‐DAG for 12 weeks. Two 4‐week nontreatment periods were placed before and after the treatment period. One hundred fourteen subjects (n = 57 in the ALA‐TAG group, n = 57 in the ALA‐DAG group) were enrolled into the analysis set for efficacy evaluation. RESULTS: The VFA and BMI were significantly decreased by the ALA‐DAG treatment with a treatment‐by‐time interaction compared with the ALA‐TAG treatment (P < 0.05). Additionally, the change from baseline of the fasting serum TAG concentration at week 12 was significantly decreased by ALA‐DAG treatment compared with ALA‐TAG treatment (P < 0.05). Safety parameters such as urinary measurements, hematologic parameters and blood biochemistry, and the incidence of adverse events did not differ significantly between groups, and no ALA‐DAG–associated adverse effects were detected. CONCLUSIONS: Incorporation of ALA‐DAG in a regular diet for 12 weeks may lead to a reduction in VFA, BMI, and serum TAG in men and women with overweight. John Wiley and Sons Inc. 2017-08-29 2017-10 /pmc/articles/PMC5638073/ /pubmed/28851088 http://dx.doi.org/10.1002/oby.21938 Text en © 2017 The Authors. Obesity published by Wiley Periodicals, Inc. on behalf of The Obesity Society (TOS) This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Saito, Shinichiro
Mori, Atsuko
Osaki, Noriko
Katsuragi, Yoshihisa
Diacylglycerol Enhances the Effects of Alpha‐Linolenic Acid Against Visceral Fat: A Double‐Blind Randomized Controlled Trial
title Diacylglycerol Enhances the Effects of Alpha‐Linolenic Acid Against Visceral Fat: A Double‐Blind Randomized Controlled Trial
title_full Diacylglycerol Enhances the Effects of Alpha‐Linolenic Acid Against Visceral Fat: A Double‐Blind Randomized Controlled Trial
title_fullStr Diacylglycerol Enhances the Effects of Alpha‐Linolenic Acid Against Visceral Fat: A Double‐Blind Randomized Controlled Trial
title_full_unstemmed Diacylglycerol Enhances the Effects of Alpha‐Linolenic Acid Against Visceral Fat: A Double‐Blind Randomized Controlled Trial
title_short Diacylglycerol Enhances the Effects of Alpha‐Linolenic Acid Against Visceral Fat: A Double‐Blind Randomized Controlled Trial
title_sort diacylglycerol enhances the effects of alpha‐linolenic acid against visceral fat: a double‐blind randomized controlled trial
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638073/
https://www.ncbi.nlm.nih.gov/pubmed/28851088
http://dx.doi.org/10.1002/oby.21938
work_keys_str_mv AT saitoshinichiro diacylglycerolenhancestheeffectsofalphalinolenicacidagainstvisceralfatadoubleblindrandomizedcontrolledtrial
AT moriatsuko diacylglycerolenhancestheeffectsofalphalinolenicacidagainstvisceralfatadoubleblindrandomizedcontrolledtrial
AT osakinoriko diacylglycerolenhancestheeffectsofalphalinolenicacidagainstvisceralfatadoubleblindrandomizedcontrolledtrial
AT katsuragiyoshihisa diacylglycerolenhancestheeffectsofalphalinolenicacidagainstvisceralfatadoubleblindrandomizedcontrolledtrial